When does building a Real-World Data / Real-World Evidence Analytics Platform make sense?

Building the analytics layer makes sense when a team already has licensed access to underlying RWD datasets and has strong statistical staff. The analytics — propensity scoring, survival analysis, cohort selection — are buildable with standard ML and biostatistics tooling. The data itself cannot be replicated internally.

What is the difference between RWD and RWE?

Real-World Data (RWD) refers to the raw patient-level datasets — claims, EHR records, registries. Real-World Evidence (RWE) is what you generate by analyzing that data to answer a clinical or economic question. The platforms in this category typically provide both: the data access and the analytical environment to turn data into evidence.

Bioinformatics & Scientific Data Management · Engineering, IT & AI

Should you build or buy Real-World Data (RWD) / Real-World Evidence Analytics Platform?

Real-World Data (RWD) / Real-World Evidence Analytics Platforms combine licensed patient-level datasets — insurance claims, electronic health records, specialty registries — with analytics tooling for study design, cohort selection, propensity scoring, and survival analysis, primarily to support market access submissions, HEOR studies, and post-approval safety monitoring.

The build-vs-buy decision for Real-World Data / Real-World Evidence Analytics Platforms turns on whether the core value is in the licensed data assets (which no internal team can replicate) or in the analytics layer on top (where AI tooling has lowered build costs considerably); the specifics are stable enough that the calculus has not shifted rapidly, but teams with existing RWD licenses are increasingly asking how much analytic control they actually need.

Domain: Bioinformatics & Scientific Data Management
Function: Engineering, IT & AI
Industries: Life Sciences & Pharma, Healthcare

Last assessed June 2026 · re-scored quarterly via The Continuum.

Build it, buy it, or bridge?

	Build it	Buy it	Bridge (buy, then extend)
Cost shape	Must still license underlying data; analytics build adds cost on top	Bundles data license and analytics; predictable contract structure	Existing RWD data license plus custom analytics tooling on top
Time to value	Fast for analytics layer if data is already licensed; slow otherwise	Single contract covers data and analytics; fastest path to studies	Analytic layer built over months on top of existing data agreements
Differentiation captured	Study design flexibility; custom endpoints and cohort logic	Standardized study methods; limited interface customization	Standard data, custom analytic interface and study templates
AI feasibility today	Analytics layer (propensity scoring, survival analysis) is buildable with ML tooling	Vendor packages the analytics; the data layer is not replicable internally	Build the analytics wrapper; keep vendor for data access
Who it fits	Teams with existing RWD data access and strong statistical staff	Organizations needing both data and analytics in a single contract	Teams locked into vendor data agreements who want analytic control

The B4 call

B4 has a verdict for Real-World Data (RWD) / Real-World Evidence Analytics Platform.

Build, Buy, Bridge, or Beware, with the five-dimension scorecard and the reasoning behind it. Unlock the call, and every other category, with B4 Pro.

Unlock the verdict in B4 Pro →

When building Real-World Data (RWD) / Real-World Evidence Analytics Platform makes sense

The build case exists, but it's narrower than in most software categories. If a team already has licensed access to claims data from IQVIA, Komodo, or Datavant, building the analytics layer on top is technically straightforward — propensity scoring, survival analysis, and HEOR study design are well-understood statistical methods with mature implementations in R and Python. Statistical teams with biostatistics depth can own their study design tooling and visualization stack without being constrained by a vendor's interface. What AI has done is lower the cost of this analytics layer further — custom cohort selection logic and covariate adjustment pipelines that once required significant bespoke engineering now have solid open-source starting points. The constraint is always the data, not the analytics. If a team has already negotiated the underlying data agreements and doesn't want to pay a second time for an analytics wrapper they could build themselves, the build case is real.

When buying Real-World Data (RWD) / Real-World Evidence Analytics Platform makes sense

Buying makes the clearest sense when the goal is to run RWE studies without spending time negotiating raw data agreements separately from the analytics platform. Platforms like Aetion, Flatiron, and IQVIA's RWE suite bundle the licensed patient-level data and the analytics environment in a single contract — and the licensed data is the product that matters. The analytic methods (propensity scoring, survival analysis, HEOR endpoints) are standardized across pharma; vendors have implemented them correctly and validated them for regulatory submissions. For organizations that need to generate evidence packages for market access decisions on tight timelines, the vendor's combination of compliant data, pre-validated methods, and regulatory familiarity is worth paying for. The build case disappears entirely if a team doesn't already have raw RWD data access, because no amount of analytics engineering replicates a claims dataset.

RWE platforms bundle two distinct things: licensed patient-level data assets and an analytics layer on top of them. IQVIA, Komodo Health, Flatiron, and Datavant have built their positions on the data, not the analytics. Propensity scoring, survival analysis, and HEOR study design are standardized analytic methods, and teams with statistical depth can build those layers themselves. The blocking factor is the underlying claims and EHR datasets, which no internal team can replicate.

Buying earns its keep when you need the licensed data and an analytics environment in a single contract and don't want to negotiate raw data agreements separately. The build case emerges at the analytics wrapper level, where teams that already license RWD from Aetion or TriNetX want more control over study design tooling and visualization without being locked into the vendor's interface. What AI has changed is the cost of the analytics layer, not the data layer, and that's where the economics are shifting.

Representative vendors

IQVIA (RWE)Flatiron Health and 3 more, scored in B4 Pro

B4 Pro

Get B4's actual call on Real-World Data (RWD) / Real-World Evidence Analytics Platform

→ B4's call for Real-World Data (RWD) / Real-World Evidence Analytics Platform: Build, Buy, Bridge, or Beware
→ The five-dimension scorecard and the scoring rationale
→ All 5 vendors with pricing and positioning
→ Quarterly re-scores that feed the MCP live, so your agents always query the current call
→ MCP server plus API and SDK access, and CSV/JSON export

Upgrade to B4 Pro

Prefer to read first? The book covers the framework end to end.

Frequently asked

What is a Real-World Data (RWD) / Real-World Evidence Analytics Platform?: Real-World Data / Real-World Evidence Analytics Platforms combine licensed patient-level datasets — insurance claims, electronic health records, specialty registries — with analytics tooling for study design, cohort selection, propensity scoring, and survival analysis, primarily to support market access submissions, HEOR studies, and post-approval safety monitoring.
When does building a Real-World Data / Real-World Evidence Analytics Platform make sense?: Building the analytics layer makes sense when a team already has licensed access to underlying RWD datasets and has strong statistical staff. The analytics — propensity scoring, survival analysis, cohort selection — are buildable with standard ML and biostatistics tooling. The data itself cannot be replicated internally.
When does buying a Real-World Data / Real-World Evidence Analytics Platform make sense?: Buying is the clear call when a team needs both the licensed data and the analytics environment in one place. Platforms like Aetion, Flatiron, and IQVIA bundle compliant data with pre-validated analytic methods designed for regulatory submission — that combination takes years and major data licensing relationships to replicate.
What are the main Real-World Data / Real-World Evidence Analytics Platform vendors?: Representative vendors include IQVIA (RWE), Aetion, Datavant / TriNetX, and Flatiron Health. B4 Pro scores the full set.
What is the difference between RWD and RWE?: Real-World Data (RWD) refers to the raw patient-level datasets — claims, EHR records, registries. Real-World Evidence (RWE) is what you generate by analyzing that data to answer a clinical or economic question. The platforms in this category typically provide both: the data access and the analytical environment to turn data into evidence.

The B4 Index scores every software category on two axes, strategic differentiation and AI feasibility, to classify it Build, Buy, Bridge, or Beware. See the full methodology.